Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary

Searching Database & Compiling the results...

This process involves analyzing complex genetic data and may take a moment.




PDX model details

PDX ID 410.51A
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 11
Average PDX Generation Time (days +/- SEM) 60 ± 7
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 410.51A
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
410.51A RB1 -0.761 1.180 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
410.51A RB1 -1.394 0.761 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
410.51A AKT3 1.221 4.661 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
410.51A BRAF 0.694 3.236 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
410.51A CHD7 0.929 3.809 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
410.51A MYC 0.929 3.809 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
410.51A KMT2A 0.959 3.887 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
410.51A GNAS 0.548 2.925 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 410.51A
Sample Site Right lung sub pleural tumour
Sample source Autopsy
Pathology Tumour Diagnosis None
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide

Patient Information

Patient Number 410
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 30
Consent to share data Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID 410.51A
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
410.51A AKT3 485 0.81 Missense variant '3/14 . 28.3 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
410.51A ZNF703 1030 0.51 Missense variant '1/2 0.0002802 28.6 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
410.51A GATA3 601 0.47 Missense variant '3/6 8.26E-06 26.1 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
410.51A CRLF2 462 0.31 Missense variant '6/6 . 9.837 Not provided Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500